Unknown

Dataset Information

0

Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort.

ABSTRACT: This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. NS5B RASs showed a prevalence of 14.8% (12/81) and were only detected in GT1b. Overall 38.3% (31/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically significant association was found between treatment failure and the baseline presence of specific NS5 RASs known as Y93C/H (p = 0.04).

SUBMITTER: Brandao R 

PROVIDER: S-EPMC5977216 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Characterization of <i>NS5A</i> and <i>NS5B</i> Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort.

Brandão Ruben R   Marcelino Rute R   Gonçalves Fátima F   Diogo Isabel I   Carvalho Ana A   Cabanas Joaquim J   Costa Inês I   Brogueira Pedro P   Ventura Fernando F   Miranda Ana A   Mansinho Kamal K   Gomes Perpétua P  

Viruses 20180426 5

This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. <i>NS5A</i> RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. <i>NS5B</i> R  ...[more]

Similar Datasets

Unknown Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients.
| S-EPMC6112080 | biostudies-literature
Unknown Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection.
| S-EPMC7876467 | biostudies-literature
Unknown The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
| S-EPMC5983500 | biostudies-literature
Unknown Transmission of NS5A-Inhibitor Resistance-Associated Substitutions Among Men Who Have Sex With Men Recently Infected with Hepatitis C Virus Genotype 1a.
| S-EPMC7643739 | biostudies-literature
Unknown Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.
| S-EPMC5997636 | biostudies-literature
Unknown Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.
| S-EPMC5995875 | biostudies-literature
Unknown Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.
| S-EPMC5580469 | biostudies-literature
Unknown Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
| S-EPMC3294886 | biostudies-literature
Unknown First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients.
| S-EPMC8612383 | biostudies-literature
Unknown Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.
| S-EPMC5460287 | biostudies-literature